- Chemed’s subsidiary Roto-Rooter recently acquired the territory and assets of its San Francisco, California and Fort Worth, Texas franchises for about US$20,600,000, continuing its program of bringing more operations in-house.
- This move expands Roto-Rooter’s direct control in two sizable urban markets, potentially affecting productivity, market share and overall business mix within Chemed.
- We’ll now explore how Roto-Rooter’s latest territorial expansion fits into Chemed’s broader acquisition-led growth narrative and long-term efficiency goals.
Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
Chemed Investment Narrative Recap
To own Chemed, you need to be comfortable with a two-engine model: VITAS’s hospice business heavily exposed to Medicare rules, and Roto-Rooter’s more cyclical service revenues. The latest US$20,600,000 Roto-Rooter franchise buy-ins add scale in San Francisco and Fort Worth, but do not fundamentally change the near term focus on Medicare reimbursement risk at VITAS or the pressure on Roto-Rooter from weaker residential demand and higher customer acquisition costs.
The most relevant recent announcement alongside these franchise acquisitions is Chemed’s upcoming first quarter 2026 earnings release and conference call on April 23–24. That update will be an important checkpoint on how Roto-Rooter’s in-house expansion is affecting margin efficiency, and how VITAS is progressing on Medicare Cap exposure and patient mix, all against the backdrop of earlier guidance calling for 2026 diluted EPS of US$23.25 to US$24.25.
But while acquisitions can support efficiency, investors should also be aware of the rising insurance and casualty cost risk that...
Read the full narrative on Chemed (it's free!)
Chemed's narrative projects $3.0 billion revenue and $362.8 million earnings by 2029. This requires 5.9% yearly revenue growth and about a $97.6 million earnings increase from $265.2 million today.
Uncover how Chemed's forecasts yield a $443.00 fair value, a 16% upside to its current price.
Exploring Other Perspectives
The most optimistic analysts were projecting revenue of about US$3.0 billion and earnings near US$397.1 million by 2029, yet this latest Roto Rooter expansion and the risk that paid digital lead costs could stay elevated show how quickly assumptions can be tested, so it is worth looking at how different your own view might be from theirs.
Explore 5 other fair value estimates on Chemed - why the stock might be worth just $443.00!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Chemed research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.
Contemplating Other Strategies?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com